Ridgeback Capital — Full Portfolio

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US

James Noble(Chief Executive Officer)ARAdrian Rawcliffe(Chief Executive Officer and Director)inGWGavin Wood(Chief Financial Officer)inWBWilliam Bertrand(Chief Operating Officer)inJLJohn Lunger(Chief Patient Supply Officer)inENElliot Norry(Chief Medical Officer)in

Co-investorsAVAvoro Capital AdvisorsEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalNENew Enterprise Associates (NEA)

Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis.

AI & Machine LearningBiotechHealthtechMedical DevicesThousand Oaks, US

William K. Bowes(Founder)GBGeorge B. Rathmann(First CEO)DPDavid Piacquad(Executive Officer)BMBrian M. McNamee(Executive Officer)inRobert A. Bradway(Executive Officer, Director)David J. Scott(Executive Officer)

Co-investorsASAsset Management CompanyBOBOMBOBoulder VenturesMAMayfield FundSUSunstone Capital

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

GWGregory Winter(Director)inNCNIGEL CROCKETT(Executive Officer)inNKNICHOLAS KEEN(Executive Officer)SASANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAHAhren Innovation CapitalASAstellas Venture Management LLCCACambridge Innovation CapitalDEDementia Discovery FundLOLongwood FundSRSR One Capital Management+4 more

Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.

AI & Machine LearningBiotechHealthtechMedical Devices

Joseph K. Belanoff(Chief Executive Officer and President)

Co-investorsLOLongitude CapitalMOMountain Group Capital

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

RERiley Ennis(Founder)inCharles Roberts(Founder)inGOGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRARA CapitalAGAgent CapitalAMAME Cloud VenturesANAndreessen HorowitzARArtis VenturesASAsset Management Company+15 more

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

WLWill Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSBSara Bonstein(Chief Financial Officer)inRARoger Adsett(Chief Operating Officer)MFMartina Flammer(Chief Medical Officer)inSNS. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBEBessemer Venture PartnersF-F-Prime CapitalFOForesite CapitalHEHercules Capital, Inc.OROrbiMedPRProspect Venture Partners+1 more

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Founder)inJennifer Doudna(Founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAGage1ATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalOROrbiMed+1 more

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.

BiotechHealthtechMedical Devices

Scott Koenig(Director)inEREric Risser(President and Chief Executive Officer)in

Co-investorsHAHavencrest Capital ManagementRIRiverVest Venture PartnersSASaints CapitalSASanofi VenturesLALa CaisseTPTPG

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.

BiotechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in

Co-investorsBRBrace PharmaBRBroadview VenturesMCMC Healthcare VenturesATAtlas VentureBOBoulder VenturesHEHeartland+1 more

Peloton develops connected fitness equipment and a digital fitness app that delivers personalized workout classes and training guidance to home exercisers.

ConsumerHardwareWellness & FitnessNew York, US

Graham Stanton(Founder)JFJohn Foley(Founder)inHKHisao Kushi(Founder)inPSPeter Stern(Chief Executive Officer and President)inElizabeth Coddington(Chief Financial Officer)NCNick Caldwell(Chief Product Officer)in

Co-investorsANAnsa CapitalBLBlue CollectiveBUBullishCACade VenturesCOCoatue ManagementFEFELIX CAPITAL+22 more

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

MKMATTHEW KANE(Executive Officer, Director)JSJeff Smith(Co-founder)inDJDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMAMichael Amoroso(President, Chief Executive Officer)in

BoardRAROBERT ADELMAN(Director)

Co-investorsAGage1AGAgent CapitalALAliment CapitalBRBrace PharmaF-F-Prime CapitalOCOCV Partners+6 more

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.

BiotechDeep TechMedical DevicesSouth San Francisco, US

TLTim Lu(Co-Founder and Chief Executive Officer)inPLPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYLYvonne Li(Executive Officer)inJames Collins(Director)Timothy Lu(Founder)

Co-investorsEVEvolution VC PartnersFLFlucas VenturesGAGaingelsGRGreen Sands EquityLILifeforce CapitalLILifeSci Venture Partners+13 more

Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.

BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

William J. Newell(Executive Officer, Director)JCJane Chung(Chief Executive Officer)inHGHans-Peter Gerber(Chief Scientific Officer)inDPDavid Pauling(Chief Administrative Officer and General Counsel)inJFJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in

Co-investorsOWOwl CapitalSASamsara BioCapitalSOSolasta VenturesSVSV Health InvestorsVIVida Ventures

Jean-Paul Clozel(Founder)

Co-investorsSOSofinnova VenturesJOJohnson & Johnson Innovation – JJDC

A biopharmaceutical company with over 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases.

BiotechHealthtech

Co-investorsBIBioBritDADag Ventures

Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.

Co-investorsARARCH Venture PartnersFRFrazier Life SciencesBOBoulder Ventures

Arrowhead Pharmaceuticals develops RNAi-based therapeutics using its targeted RNAi molecule (TRiM) platform, which silences disease-causing genes for conditions with significant unmet medical needs.

Biotech

BioMarin is a biotechnology company that develops medicines derived from genetic discoveries to treat serious and rare diseases.

BiotechHealthtech

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalFOForesite CapitalNENextech InvestRARA CapitalWEWellington ManagementTHThird Rock Ventures

Cellectis is a biotech company focused on cell therapy and immunotherapy.

AgTechAI & Machine LearningBiotechDeep TechHealthtech

Developed targeted cancer therapies with companion diagnostics (Rubraca); IPO'd in 2011 (NASDAQ: CLVS).

Patrick Mahaffy(Founder)in

Co-investorsAIAisling CapitalFRFrazier Life SciencesNENew Enterprise Associates (NEA)PFPfizer Venture Investments

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

LLLou Lange(Founder)MLMichael L. Riordan(Founder)inDODaniel O'Dayin

Co-investorsAIAisling CapitalASAsset Management CompanyFRFrazier Life SciencesKLKleiner PerkinsLOLongitude CapitalLULumira Ventures+5 more

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsACAccess BiotechnologyBABain Capital Life SciencesOXOxford Bioscience PartnersRARA Capital

Victoria Richonin

Co-investorsKLKleiner Perkins

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.

BiotechHealthtechSan Francisco, US

Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)inRory Riggs(Founder)

BoardRBRory B. Riggs(Director)

Co-investorsAVAvalon BioVenturesFOForesite CapitalSCScientia VenturesMAMaverick Ventures

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases.

BiotechDigital HealthMedical DevicesBoston, US

Alexis Borisy(Founder)Eric Lander(Founder)Levi Garraway(Founder)Todd Golub(Founder)

Co-investorsGVGV (Google Ventures)KHKhosla VenturesKLKleiner PerkinsNSNSG VenturesANAndreessen HorowitzCACasdin Capital+1 more

Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.

South San Francisco, US

JSJohn Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in

BoardKSKevin Starr(Director)inCharles Homcy, M.D.(Director)

Co-investorsAIAisling CapitalAVAvoro Capital AdvisorsRARA CapitalTHThird Rock VenturesWEWellington Management

GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with an R&D pipeline of eight programs focused on acute-on-chronic liver failure, hepatic encephalopathy, cholangiocarcinoma, and urea cycle disorders/organic acidemias.

BiotechHealthtech

Co-investorsREredalpine

A research-intensive biopharmaceutical company that develops medicines and vaccines.

BiotechHealthtechSouth San Francisco, US

Luke Nathaniel Walker(Executive Officer)JEJulie Eastland(Executive Officer, Director)in

BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)

Co-investorsK2K2 HealthVenturesTATaiho Ventures, LLCARArix BioscienceLILilly Asia VenturesMPMPM BioImpactNENew Leaf Venture Partners+1 more

Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.

BiotechHealthtechBurlingame, US

Daniel J. Capon(Director)CMCarin Mueller Rollins(Co-Founder & Chief Operating Officer)HEHarold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)PBPaul Brunetta(Chief Medical Officer)in

Co-investorsPOPoint72AGAgent CapitalBABaruch Future VenturesINInVivium Capital

Immutep is a late clinical-stage biotechnology company developing immunotherapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune molecule to treat cancer and autoimmune diseases.

BiotechHealthtech

Incyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas.

BiotechHealthtechMedical DevicesWilmington, US

BMBill Meury(Chief Executive Officer)inPJPablo J. Cagnoni(President, Incyte and Global Head of R&D)in

Co-investorsDEDecheng Capital

Intellia is a consulting firm that helps public sector organizations transform their services by integrating digital solutions, reducing costs, and managing workforce transitions.

GovTech

Co-investorsFAFatima Gobi VenturesGOGobi PartnersOROrbiMed

Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.

BiotechHealthtechMedical Devices

Co-investorsAIAisling CapitalBIBioBritSASamsara BioCapital

InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.

daniel welchinScott Harkonen(Founder)

Co-investorsSASanderling VenturesSOSofinnova VenturesNENew Enterprise Associates (NEA)

Ionis Pharmaceuticals is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted medicines using its antisense chemistry platform for people with serious diseases.

BiotechCarlsbad, US

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechDigital HealthHealthtechCambridge, US

PMPETER M. HECHT(Executive Officer, Director)inMGMARK G. CURRIE(Executive Officer)inHEHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)TATHOMAS A. MCCOURT(Executive Officer)in

BoardTGTERRANCE G. MCGUIRE(Director)

Co-investorsF-F-Prime CapitalMOMountain Group CapitalVEVenrockMAMaverick VenturesPOPolaris Partners

Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.

BiotechSeattle, US

Hans Bishop(Executive Officer, Director, Promoter)Richard Klausner(Director, Promoter)Bernard J. Cassidy(Executive Officer)Robert Azelby(Executive Officer)Sunil Agarwal(Executive Officer)Rupert Vessey(Director)

Co-investorsARARCH Venture PartnersBEBezos ExpeditionsALAlaska Permanent Fund CorporationCRCrestline InvestorsVEVenrock

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inAPANNA PROTOPAPAS(Executive Officer, Director)TLTimothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsBABain Capital Life SciencesF-F-Prime CapitalLILightstone VenturesNENew Enterprise Associates (NEA)NENextech InvestPFPfizer Venture Investments+3 more

BiotechHealthtech

Jean-Paul Kress, M.D.in

Co-investorsATAtlas VentureBABayern Kapital

Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity.

BiotechLongevityMedical Devices

Steven Perrin(President and Chief Scientific Officer)

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCUCurative VenturesFOForesite CapitalNENextech InvestTHThe Column GroupVIVida Ventures

Bob Dugganin

Co-investorsASAsset Management CompanyKLKleiner PerkinsVEVenrock

BiotechBoston, US

DDDarlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDMDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in

BoardChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)

Co-investorsBIBiotechnology Value FundFRFrazier Life SciencesOROrbiMed

San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.

BiotechSan Diego, US

MBMarcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRSRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJSJames Schmidt(Executive Officer)inCMChrysa Mineo(Executive Officer)in

Co-investorsARARCH Venture PartnersOUOUP (Osage University Partners)VEVenrockLILilly Ventures

Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.

BiotechHealthtechTarrytown, US

Co-investorsSASanderling VenturesVEvenBio PartnersWIWireframe Ventures

Reverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.

AI & Machine LearningBiotechHealthtechBoston, US

AGAnkit Gupta(CTO)inCDConnor Duffy(Founder)inJKJonah Kallenbach(Founder)inDoug Hamilton(Principal Talent Acquisition Partner)

Co-investorsDODorm RoomLILifeforce CapitalRURuvento Ventures Pte Ltd.UNUNCOMMON DENOMINATORWIWireframe VenturesWOWormhole Capital+17 more

Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy.

BiotechDeep TechHealthtechMedical DevicesUnknown based on the provided page content, US

SMSandy Macrae(Chief Executive Officer)in

Co-investorsCACalifornia Technology VenturesFOFoothill VenturesFOForesite Capital

Scout is an AI-native reporting and analytics platform designed for CPG (consumer packaged goods) sales teams, automating the conversion of POS and syndicated data into dashboards, reports, and narratives for retail negotiations.

AI & Machine LearningConsumerData & InfrastructureEnterprise SoftwareRetail TechSaaSSan Francisco, US

SZSasha Zhang(CEO)inJordan Wickmd143rbh7f md143rbh7f(Consultant)

Co-investorsHOHolland CapitalTHThe E14 FundY Y CombinatorALAlign VenturesBOBooz Allen VenturesDEDecisive Point+3 more

SeaGen develops automated robots that monitor aquatic ecosystems and remove pollutants while supporting the growth of beneficial species like seaweed to improve food and water security and reduce atmospheric carbon.

CleantechClimate TechRobotics

Co-investorsAEAera VCALAlly Bridge GroupRARA CapitalT.T. Rowe Price

BiotechHealthtechMedical DevicesNew York, US

Charles Pfizer

Co-investorsSOSofinnova Ventures

GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients.

BiotechHealthtechLondon, GB

Mary Lynne Hedley(Executive Officer, Director)Leon O. Moulder, Jr.(Executive Officer, Director)JHJeffrey Hanke(Executive Officer)Joseph L. Farmer(Executive Officer)inGrant C. Bogle(Executive Officer)Martin H. Huber(Executive Officer)

Co-investorsKLKleiner PerkinsNENew Enterprise Associates (NEA)PAPappas CapitalAVAvoro Capital Advisors

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

MKMatthew Kapustain

Co-investorsADAdvent Life SciencesALALS Investment FundFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSFOForbion

Vertex provides a governance-preserving 3D access layer that streams context-aware pixels from product lifecycle management (PLM) systems to manufacturing, suppliers, and operations teams without exporting derivative geometry files.

Advanced ManufacturingEnterprise Software

Co-investorsNENext Level VenturesSBSBI JI Innovation Advisory Ltd.HYHyde Park Angels